JP2007520525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520525A5 JP2007520525A5 JP2006551843A JP2006551843A JP2007520525A5 JP 2007520525 A5 JP2007520525 A5 JP 2007520525A5 JP 2006551843 A JP2006551843 A JP 2006551843A JP 2006551843 A JP2006551843 A JP 2006551843A JP 2007520525 A5 JP2007520525 A5 JP 2007520525A5
- Authority
- JP
- Japan
- Prior art keywords
- alkoxy
- alkyl
- cycloalkoxy
- cycloalkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 161
- -1 cycloalkoxy-alkoxy Chemical group 0.000 claims 113
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 110
- 125000002837 carbocyclic group Chemical group 0.000 claims 95
- 125000000753 cycloalkyl group Chemical group 0.000 claims 95
- 125000000623 heterocyclic group Chemical group 0.000 claims 95
- 125000003367 polycyclic group Chemical group 0.000 claims 95
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 87
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 82
- 125000003545 alkoxy group Chemical group 0.000 claims 82
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 82
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 82
- 125000001475 halogen functional group Chemical group 0.000 claims 82
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 82
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 82
- 125000001424 substituent group Chemical group 0.000 claims 82
- 125000002950 monocyclic group Chemical group 0.000 claims 81
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims 69
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 68
- 150000001408 amides Chemical class 0.000 claims 42
- 125000003368 amide group Chemical group 0.000 claims 40
- 229910052739 hydrogen Inorganic materials 0.000 claims 37
- 239000001257 hydrogen Substances 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims 29
- 150000002431 hydrogen Chemical class 0.000 claims 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 14
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 claims 14
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 13
- 241000255925 Diptera Species 0.000 claims 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 8
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- GSYXWWRJAJFUQP-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-5-[2-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,3-thiazol-5-yl]-1,3-thiazole Chemical group C1N(CC2)CCC2C1OC(S1)=NC=C1C(S1)=CN=C1OC(C1)C2CCN1CC2 GSYXWWRJAJFUQP-UHFFFAOYSA-N 0.000 claims 1
- LGEQFVDWSRNGCB-UHFFFAOYSA-N 3-[5-[5-(1-azabicyclo[2.2.2]octan-3-yloxy)furan-2-yl]furan-2-yl]oxy-1-azabicyclo[2.2.2]octane Chemical group C1N(CC2)CCC2C1OC(O1)=CC=C1C(O1)=CC=C1OC(C1)C2CCN1CC2 LGEQFVDWSRNGCB-UHFFFAOYSA-N 0.000 claims 1
- PBCZZHRZTKQCAO-UHFFFAOYSA-N 3-[5-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridin-3-yl]pyridin-2-yl]oxy-1-azabicyclo[2.2.2]octane Chemical group C1N(CC2)CCC2C1OC(N=C1)=CC=C1C(C=N1)=CC=C1OC(C1)C2CCN1CC2 PBCZZHRZTKQCAO-UHFFFAOYSA-N 0.000 claims 1
- UNDYYQLZRMLSGW-UHFFFAOYSA-N 3-[6-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical group C1N(CC2)CCC2C1OC(N=N1)=CC=C1C(N=N1)=CC=C1OC(C1)C2CCN1CC2 UNDYYQLZRMLSGW-UHFFFAOYSA-N 0.000 claims 1
- KYMGLSXKGNAILG-UHFFFAOYSA-N 4-[6-[2-[6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)pyridazin-3-yl]sulfanylphenyl]sulfanylpyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1SC1=CC=CC=C1SC(N=N1)=CC=C1N1CCN2CCC1CC2 KYMGLSXKGNAILG-UHFFFAOYSA-N 0.000 claims 1
- KGIRAZYZPLKXRU-UHFFFAOYSA-N 4-[6-[3-[6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)pyridazin-3-yl]sulfanylphenyl]sulfanylpyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1SC(C=1)=CC=CC=1SC(N=N1)=CC=C1N1CCN2CCC1CC2 KGIRAZYZPLKXRU-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 210000004246 corpus luteum Anatomy 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 230000001856 erectile effect Effects 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 201000009863 inflammatory diarrhea Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 0 CC1(**)SCCS1 Chemical compound CC1(**)SCCS1 0.000 description 7
- SIJBDWPVNAYVGY-UHFFFAOYSA-N CC1(C)OCCO1 Chemical compound CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 description 4
- MJOPSVYHCVFHDW-UHFFFAOYSA-N CC1(C)N(C)CCN1 Chemical compound CC1(C)N(C)CCN1 MJOPSVYHCVFHDW-UHFFFAOYSA-N 0.000 description 1
- YFDRYBUJCGOYCQ-UHFFFAOYSA-N CN1C(C2)CNC2C1 Chemical compound CN1C(C2)CNC2C1 YFDRYBUJCGOYCQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400170 | 2004-02-04 | ||
| US54175204P | 2004-02-05 | 2004-02-05 | |
| PCT/EP2005/050403 WO2005075479A1 (en) | 2004-02-04 | 2005-02-01 | Dimeric azacyclic compounds and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007520525A JP2007520525A (ja) | 2007-07-26 |
| JP2007520525A5 true JP2007520525A5 (enExample) | 2008-03-06 |
Family
ID=34839642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551843A Pending JP2007520525A (ja) | 2004-02-04 | 2005-02-01 | 二量体のアザ環式化合物及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7674899B2 (enExample) |
| EP (1) | EP1713809B1 (enExample) |
| JP (1) | JP2007520525A (enExample) |
| AT (1) | ATE437880T1 (enExample) |
| DE (1) | DE602005015682D1 (enExample) |
| WO (1) | WO2005075479A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004083388A2 (en) | 2003-03-14 | 2004-09-30 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| EP3205644A1 (en) | 2005-12-29 | 2017-08-16 | Celtaxsys Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| EP1991528A2 (en) * | 2006-01-18 | 2008-11-19 | Siena Biotech S.p.A. | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
| WO2008067121A2 (en) * | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| CL2008000119A1 (es) | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
| EP2188288A1 (en) | 2007-09-11 | 2010-05-26 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole n-oxides |
| WO2014164658A1 (en) | 2013-03-12 | 2014-10-09 | Celtaxsys, Inc. | Methods of inhibiting leukotriene a4 hydrolase |
| CA2906086A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| CA2906084A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| EP2968264A4 (en) | 2013-03-14 | 2016-11-02 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
| US10183938B2 (en) | 2014-12-16 | 2019-01-22 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors |
| JP2018516973A (ja) | 2015-06-10 | 2018-06-28 | フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物 |
| EP3334740A4 (en) | 2015-08-12 | 2019-02-06 | Axovant Sciences GmbH | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS |
| EP3458052B1 (en) | 2016-05-17 | 2019-11-06 | Scandion Oncology A/S | Combination treatment of cancer |
| ES3014615T3 (en) | 2018-05-31 | 2025-04-23 | Celltaxis Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5821371A (en) | 1994-10-24 | 1998-10-13 | Eli Lilly And Comany | Heterocyclic compounds and their preparation and use |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| US6579878B1 (en) | 2000-07-07 | 2003-06-17 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| MXPA05004723A (es) * | 2002-11-01 | 2005-12-05 | Pharmacia & Upjohn Co Llc | Compuestos que tienen ambas actividades del agonista alfa 7 nachr y el antagonista 5ht para el tratamiento de las enfermedades del snc. |
| CA2510296A1 (en) | 2002-12-20 | 2004-07-15 | Control Delivery Systems, Inc. | Steroid compositions for intraocular use |
| ATE445618T1 (de) | 2003-02-27 | 2009-10-15 | Neurosearch As | Neue diazabicyclische arylderivate |
-
2005
- 2005-02-01 AT AT05716605T patent/ATE437880T1/de not_active IP Right Cessation
- 2005-02-01 WO PCT/EP2005/050403 patent/WO2005075479A1/en not_active Ceased
- 2005-02-01 DE DE602005015682T patent/DE602005015682D1/de not_active Expired - Lifetime
- 2005-02-01 US US10/586,838 patent/US7674899B2/en not_active Expired - Fee Related
- 2005-02-01 JP JP2006551843A patent/JP2007520525A/ja active Pending
- 2005-02-01 EP EP05716605A patent/EP1713809B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520525A5 (enExample) | ||
| JP2009538867A5 (enExample) | ||
| JP2004538268A5 (enExample) | ||
| CN100432075C (zh) | 作为烟碱样乙酰胆碱受体配体的二氮杂双环芳基衍生物 | |
| CA2389553A1 (en) | Heteroaryl-diazabicycloalkanes | |
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| JP2006508109A5 (enExample) | ||
| JP2008530172A5 (enExample) | ||
| JP2005538187A5 (enExample) | ||
| JP2009538869A5 (enExample) | ||
| JP2009538870A5 (enExample) | ||
| JP2005524713A5 (enExample) | ||
| JP2009538866A5 (enExample) | ||
| JP2008530171A5 (enExample) | ||
| US7750011B2 (en) | Diazabicyclic aryl derivatives and their medical use | |
| JP2009526814A5 (enExample) | ||
| JP2009537599A5 (enExample) | ||
| JP2009526776A5 (enExample) | ||
| EP1562945A1 (en) | 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof | |
| EP1713809B1 (en) | Dimeric azacyclic compounds and their use | |
| JP2007530635A5 (enExample) | ||
| JP2008530172A (ja) | ジアザ二環系アリール誘導体及びそれらのニコチン様アセチルコリン受容体におけるコリン作動性リガンドとしての使用 | |
| WO2007068475A1 (en) | (1-aza-bicyclo[3.3.1] n0n-4-yl)-[5-(ih-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disorders | |
| JP2009518357A5 (enExample) | ||
| KR20050062575A (ko) | 신규한 1,4-디아자바이사이클로알칸 유도체, 이의 제법 및용도 |